Margaret Nagel, M.D., is board-certified in pediatrics and works with children and families at Children's Health℠. Dr. Nagel has a specialized clinical interest in treating children diagnosed with solid tumors, including rhabdomyosarcoma and other soft tissue sarcomas. She is an Assistant Professor of Pediatrics in the Department of Hematology and Oncology at UT Southwestern.
She earned two master’s degrees – Master of Healthcare Administration and Management and a Master of Biomedical Science. She earned her medical degree from Rosalind Franklin University, Chicago Medical School, and completed her residency in pediatrics at the University of Tennessee Health Science Center. Dr. Nagel went on to complete two fellowships – a solid tumor fellowship and a pediatric hematology/oncology fellowship – at St. Jude Children's Research Hospital.
Dr. Nagel is a member of the Children’s Oncology Group, the American Academy of Pediatrics and the American Society of Pediatric Hematology/Oncology. She is the recipient of many awards and honors, including the Southern Society of Pediatric Research Resident Trainee Travel Award, the Resident of the Month and Upsilon Phi Delta, National AUPHA Honor Society for Health Administration.
She is a researcher that has evaluated the role of DLK1 in fusion-negative rhabdomyosarcoma. In addition to her published work, she is a requested presenter at regional and national conferences. Dr. Nagel has presented on histiocytic disorders, navigating post-transplant lymphoproliferative disease and treatment of sickle cell nephropathy.
Dr. Nagel says it’s an honor caring for children. She loves supporting patients and their families as they navigate treatment, celebrate good days and work through the hard ones. During her free time, she enjoys traveling with her family, swimming and reading.
Education and Training
- Medical School
- Rosalind Franklin University - Chicago Medical School (2015)
- University of Tennessee Health Science Center (2018), Pediatrics
- St. Jude Children's Research Hospital (2022), Solid Tumor
St. Jude Children's Research Hospital (2021), Pediatric Hematology/Oncology
- Board Certification
- American Board of Pediatrics/Hematology-Oncology
Departments and Programs
- Solid tumors
- Adolescent and young adult cancers
- Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus. Nagel MB, Ryder A, Lobbins M, Bhatt N, Pediatric blood & cancer 2021 01 68 1 e28534
- American Academy of Pediatrics
- American Society of Pediatric Hematology and Oncology
- Children’s Oncology Group
Awards and Honors
- Resident Trainee Travel Award 2018, Southern Society for Pediatric Research
- Resident of the Month 2015, Le Bonheur Children’s Hospital
- Scholarship Award for the highest average in basic sciences 2015, Chicago Medical School
- Upsilon Phi Delta Honor Society for Health Administration 2013, National Association of University Programs in Health Administration